Bernstein·2026-11-04CompanyOutperform$608 → $620▲Vertex Pharmaceuticals Inc (VRTX.US) VRTX 3Q26: Vertex is our top pick because it's cystic fibrosis technical moat is one of a kind across biotechnology biopharmaceuticalsVRTX.US·Top pick
Morgan Stanley·2026-10-25CompanyOverweight$665Vertex Pharmaceuticals (VRTX.US): Takeaways from ASN on emerging kidney franchise
BofA Securities·2026-10-16CompanyBuy$667Vertex Pharmaceuticals Inc. (VRTX.US) VRTX Week: CAH deep dive on atumelnant
UBS·2026-09-28CompanyBuy$585 → $615▲Vertex Pharmaceuticals Inc (VRTX.US) -Slides- AMKD Deep Dive + Doc Call: Pot’l $2-3B and Phase III Data Early 2027
Goldman Sachs·2026-10-25SectorBuy$654Healthcare: Biotechnology: Takeaways from the American Society of Nephrology meeting
Goldman Sachs·2026-10-15SectorAmericas Healthcare: Biotechnology: 3Q earnings preview: Navigating macro and idiosyncratic crosscurrents